David Einstein (@davidjeinstein) 's Twitter Profile
David Einstein

@davidjeinstein

Disease Group Leader, GU Medical Oncology @BIDMChealth @df_hcc, Asst Prof @harvardmed, dad, cyclist, Far Side superfan

ID: 2979168849

linkhttps://connects.catalyst.harvard.edu/Profiles/display/Person/132809 calendar_today15-01-2015 01:33:52

928 Tweet

697 Takipçi

635 Takip Edilen

David Einstein (@davidjeinstein) 's Twitter Profile Photo

Incredibly important to remember that “standard of care” is not always guaranteed in control arms, and therefore any “benefits” may be artificial.

Crying Wolf (@oncologycompany) 's Twitter Profile Photo

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more | BMJ Oncology bmjoncology.bmj.com/content/3/1/e0…

David Yang (@dyangmd) 's Twitter Profile Photo

Excited to share work with coauthors Leslie Lee, Katie Lee Martin King and others on "AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer." A tweetorial: 1/n

Matt Cooperberg (@dr_coops) 's Twitter Profile Photo

I’ve read a lot of hand-wringing post-game articles today…but this quote keeps coming to mind to sum it all up 🤦‍♂️

I’ve read a lot of hand-wringing post-game articles today…but this quote keeps coming to mind to sum it all up 🤦‍♂️
Sizun Jiang (@sizunj) 's Twitter Profile Photo

🔬 Exciting joint postdoc opportunity between Brooke E. Howitt Stanford Medicine and us BIDMC Harvard Medical School! Join us in advancing cancer research through computational & spatial genomics. Focus on gynecologic cancers & womens health at Boston/Stanford nature.com/naturecareers/…

Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

Taking applications for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by Andrea Apolo, M.D. and myself! Secure your spot for two days of professional development and networking here: forms.gle/jMG7iKfAYomuad…  UroToday.com Prostate Cancer Foundation Phillip Koo, MD

Mark C. Markowski (@markowskiguonc) 's Twitter Profile Photo

Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.

Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.
Dana-Farber Lank Center for Genitourinary Oncology (@danafarber_gu) 's Twitter Profile Photo

This summer: OncLive.com State of the Science Summit on GU malignancies. Collaborative across Dana-Farber/Harvard Cancer Center programs, featuring from the Lank Center Alicia Morgans, MD, MPH on prostate cancer and Wenxin (Vincent) Xu on kidney cancer. More info in the flyer below 👇

This summer: <a href="/OncLive/">OncLive.com</a> State of the Science Summit on GU malignancies. Collaborative across Dana-Farber/Harvard Cancer Center programs, featuring from the Lank Center <a href="/CaPsurvivorship/">Alicia Morgans, MD, MPH</a> on prostate cancer and <a href="/VincentWenxinXu/">Wenxin (Vincent) Xu</a> on kidney cancer. More info in the flyer below 👇
Ravi A Madan M.D. (@dr_ravimadan) 's Twitter Profile Photo

What should we do for #ProstateCancer patients with #PSMA+ #BCR? While we can use any treatment do we NEED to? Stop by tomorrow abstract BD# 297. Monday 9am-noon The answer is pretty clear… #ASCO25 ASCO National Cancer Institute

What should we do for #ProstateCancer patients with #PSMA+ #BCR?

While we can use any treatment do we NEED to?

Stop by tomorrow abstract BD# 297. Monday 9am-noon

The answer is pretty clear…

#ASCO25 <a href="/ASCO/">ASCO</a> <a href="/theNCI/">National Cancer Institute</a>